AbbVie Inc
Common Stock · USD · XETRA
Price
$216.5
Cap
—
Earnings
—
30d Trend
+9.4%
25% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 56×Macro 0.99 (−1%)=55
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 80%
BRAIN47 HORIZON ANALYSIS
Moderate long-term case — not compelling enough for a multi-year commitment
BRAIN47'S ASSESSMENT
I rate AbbVie Inc at 55/100 — a STRONG reading on the Brain47 Signal. The strongest factor is risk management at 65/100. I classify this as a growth position with the strongest thesis on a long-term horizon.
PAST PERFORMANCE
1 MONTH
+9.0%
3 MONTHS
-6.4%
12 MONTHS
+21.5%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
Moderate long-term case — not compelling enough for a multi-year commitment. low-risk profile and Technical (61) are the primary strengths. Historical volatility is normal at 25%. I classify this as a growth position — positive trend direction combined with growth potential points to capital appreciation.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.